Retail pharmacies in the US will be able to dispense mifepristone-based therapies to end pregnancies after the FDA introduced changes to its regulatory framework for the products.<
The first and only body-identical HRT for post-menopausal oestrogen deficiency, Bijuve, has been passed by the SMC as suitable for use by Scotland’s National Health Service, after being adv
Astellas remains on course to be the first drugmaker to bring a new non-hormonal therapy for symptoms of menopause to market, after the FDA started a review of its orally-active neurokinin-
